Prairiewood Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Prairiewood Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,165	Closed	-$547K	–	77
2022 Q2	$547K	Hold	50,165	–	–	0.43%	41
2022 Q1	$567K	Buy	50,165 +35,087	+233%	+$461K	0.4%	46
2021 Q4	$237K	Hold	15,078	–	–	0.19%	66
2021 Q3	$258K	Hold	15,078	–	–	0.21%	62
2021 Q2	$324K	Sell	15,078 -9,711	-39%	-$174K	0.28%	59
2021 Q1	$372K	Sell	24,789 -35,475	-59%	-$574K	0.34%	55
2020 Q4	$792K	Buy	+60,264	New	+$725K	0.81%	39

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prairiewood Capital's VNDA Position: Q3 2022 in Review

Prairiewood Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2022, closing a stake of 50,165 shares — an estimated $547K sold.

Prairiewood Capital first reported a position in VNDA in Q4 2020 and held it in 7 quarters. The position peaked at $792K in Q4 2020. 178 funds tracked by Wall St. Rank hold VNDA as of Q3 2022.

Prairiewood Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Prairiewood Capital sold 50,165 Vanda Pharmaceuticals shares in Q3 2022, an estimated $547K.
Prairiewood Capital first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Prairiewood Capital's Vanda Pharmaceuticals position peaked at $792K in Q4 2020.
178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2022.

Based on Prairiewood Capital's 13F filing for Q3 2022, filed 13 Oct 2022.